Wu Chii-Huei, Lee Mey-Fann, Yang Jyh-Shyne, Tseng Ching-Yuan
Department of Education and Research, Taichung Veterans General Hospital, 160 Chung Kang Road, Section 3, Taichung 407, Taiwan.
Mol Immunol. 2002 Nov;39(7-8):459-64. doi: 10.1016/s0161-5890(02)00145-1.
Cockroach is one of the major indoor allergens for IgE-mediated allergic respiratory illnesses throughout the world. The American cockroach (Periplaneta americana) Per a 1 allergen is antigenically cross-reactive with the German cockroach (Blattella germanica) Bla g 1 allergen. The aim of this study was to identify linear B cell epitopes of Per a 1 that are recognized by human IgE. Per a 1 deletion mutants were generated from the recombinant Per a 1.0104 allergen (274 amino acid residues), and antigenicities were assessed by immunoblotting, enzyme-linked immunosorbent assay (ELISA), and binding inhibition. Human atopic sera were not able to recognize deletion mutants consisting of amino acids 1-77, 86-205, and 200-266. However, human sera did recognize the N-terminal mutant containing amino acids 1-87 and the C-terminal mutant containing amino acids 200-274, demonstrating positive IgE binding that was heterogeneously distributed among the different sera tested. Amino acid residues 78-85 and 267-274, containing internal repeats, were shown to be required for IgE binding to the Per a 1.0104 protein. Two peptides corresponding to these IgE-binding amino acid sequences were synthesized. Peptide 78-85 showed a positive IgE interaction with 80% of the sera, while peptide 267-274 was capable of IgE binding to all of the sera tested. Moreover, preincubation of atopic sera with IgE-positive recombinants and peptides resulted in marked inhibition of the IgE binding to purified Per a 1.0104 allergen. Amino acid sequences 78LIRALFGL85 and 267IRSWFGLP1274 of the American cockroach Per a 1.0104 allergen were involved in IgE binding. These findings will advance the understanding of the specific reactivity of the epitopes of cockroach allergens, thereby contributing to the development of specific immunotherapies for clinical use.
蟑螂是全球范围内引起IgE介导的过敏性呼吸道疾病的主要室内过敏原之一。美洲大蠊(Periplaneta americana)的Per a 1过敏原与德国小蠊(Blattella germanica)的Bla g 1过敏原具有抗原交叉反应性。本研究的目的是鉴定人IgE识别的Per a 1线性B细胞表位。从重组Per a 1.0104过敏原(274个氨基酸残基)产生Per a 1缺失突变体,并通过免疫印迹、酶联免疫吸附测定(ELISA)和结合抑制评估抗原性。特应性人血清无法识别由氨基酸1 - 77、86 - 205和200 - 266组成的缺失突变体。然而,人血清确实识别含有氨基酸1 - 87的N端突变体和含有氨基酸200 - 274的C端突变体,表明阳性IgE结合在不同测试血清中呈异质性分布。含有内部重复序列的氨基酸残基78 - 85和267 - 274被证明是IgE与Per a 1.0104蛋白结合所必需的。合成了与这些IgE结合氨基酸序列相对应的两种肽。肽78 - 85与80%的血清显示出阳性IgE相互作用,而肽267 - 274能够与所有测试血清发生IgE结合。此外,特应性血清与IgE阳性重组体和肽的预孵育导致对纯化的Per a 1.0104过敏原的IgE结合受到显著抑制。美洲大蠊Per a 1.0104过敏原的氨基酸序列78LIRALFGL85和267IRSWFGLP1274参与了IgE结合。这些发现将推进对蟑螂过敏原表位特异性反应性的理解,从而有助于开发用于临床的特异性免疫疗法。